Clinical trials: Pulmonary Function Assessment
Asthma
A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
This study will be a repeat-dose, double-blind, randomized, placebo controlled, three-way crossover study in patients with persistent bronchial asthma to compare the effect of morning (AM) and evening (PM) dosing with fluticasone…
- Trial name
- NCT01287065
- Testing
- FF(100mcg)/Vilanterol(25mcg) AM, FF(100mcg)/Vilanterol(25mcg) PM
- Where
- New Zealand
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01521390
- Testing
- GSK573719 62.5 mcg (one strip), GSK573719 62.5 mcg(two strips), GSK573719 125 mcg (one strip)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Low Back Pain
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients…
- Trial name
- NCT00246155
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ipsen
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT03646864
- Testing
- ACT-541468
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
TLC in Patients With and Without Respiratory System Disease
Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)
A comparative study to test the efficacy of a novel device - the MiniBoxPFT, in measuring TLC (total lung capacity) compared to TLC measured by standard body plethysmography using the ZAN 500.
- Trial name
- NCT01952431
- Testing
- Total Lung Capacity (TLC) testing
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PulmOne Advanced Medical Devices, Ltd.
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19 Respiratory Infection, FLU
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
The primary objective of this study is to determine the safety and efficacy profile of the food supplement (KUNAMIN®) containing grape juice, seed, stem, and bark given to patients treated with the established treatment regimen…
- Conditions
- COVID-19 Respiratory Infection, FLU, Cold; Influenza, Bacterial Pneumonia
- Trial name
- NCT05417997
- Testing
- Kunamin®, Favipiravir, Enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- RAAS Nutritionals, LLC
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
COPD
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
This study purpose is to further study the profiles of glycopyrronium (NVA237) and tiotropium during the first hours after dosing and their impact on pulmonary function, COPD symptoms and ability to perform daily activities by…
- Trial name
- NCT01959516
- Testing
- Glycopyrronium, Tiotropium
- Where
- 21 sites in Germany, Italy and 2 more
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model.
- Trial name
- NCT06592768
- Testing
- Briquilimab
- Where
- 6 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Jasper Therapeutics, Inc.
Cystic Fibrosis
Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in 2 different decades in terms of FEV1 (Forced Expiratory Volume in one second) maintenance.
- Trial name
- MAESTRALE (NCT01651455)
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
- Trial name
- LABD (NCT00791518)
- Testing
- No intervention
- Where
- 57 sites in United States
- Volunteers
- 1,084 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging
In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.
- Trial name
- NCT02451540
- Testing
- HRCT scan, Roflumilast
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- FLUIDDA nv
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323621
- Testing
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Salbutamol as needed
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Atelectases, Postoperative Pulmonary
The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 3
The Effectiveness of the Jamboxx Respiratory Therapy Device in Treatment of Patients with Decreased Respiratory Function is a proposal for investigation of the application of gaming to improving respiratory health.
- Trial name
- NCT03547349
- Testing
- Digital Incentive Spirometer, Jamboxx Respiratory Therapy Device
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- My Music Machines Inc.
Pulmonary Disease, Chronic Obstructive
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale.
- Trial name
- NCT00354666
- Testing
- GSK159797
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a…
- Trial name
- NCT06979323
- Testing
- Depemokimab
- Where
- 50 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline